<DOC>
	<DOCNO>NCT00007072</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine safety efficacy azacitidine phenylbutyrate treatment patient thalassemia major .</brief_summary>
	<brief_title>Phase II Study Azacitidine Phenylbutyrate Patients With Thalassemia Major</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive azacitidine IV continuously day 1-4 oral phenylbutyrate three time day day 14-42 . Bone marrow needle aspiration perform day 6 , 14 , 42 assess disease response treatment . If response day 42 , second course azacitidine phenylbutyrate begin 7 day later . Patients follow weekly 3 month monthly thereafter .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis thalassemia major Progressive disease define : Increasing transfusion requirement difficulty maintenance hemoglobin level great 7 g/dL consequence autologous allogeneic antibody OR Increasing extramedullary hematopoiesis cause compression phenomenon OR Disease complication iron overload despite traditional transfusion iron chelation therapy ( e.g. , heart failure , decrease cardiac ejection fraction , endocrinopathy , evidence progressive liver dysfunction ) Standard transfusion therapy iron chelation therapy must contraindicate Prior/Concurrent Therapy See Disease Characteristics Patient Characteristics Performance status : ECOG 02 Life expectancy : Greater 10 day Not moribund Hematopoietic : See Disease Characteristics Hepatic : See Disease Characteristics AST ALT great 3 time upper limit normal ( ULN ) Bilirubin great 1.5 time ULN ( unless due hemolysis Gilbert 's disease ) Albumin least 3 g/dL No severe concurrent hepatic disease Renal : Creatinine great 2 mg/dL Creatinine clearance least 60 mL/min No severe concurrent renal disease Cardiovascular : See Disease Characteristics No New York Heart Association class III IV Other : Not pregnant nursing No severe concurrent metabolic disease No severe sepsis septic shock No concurrent alter mental status seizure disorder No concurrent myelodysplastic syndrome leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>hematologic disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>thalassemia major</keyword>
</DOC>